logo
Share SHARE
FONT-SIZE Plus   Neg

Regeneron Says Australian TGA Granted Approval For EYLEA To Bayer Healthcare

Regeneron Pharmaceuticals Inc (REGN) along with Bayer Healthcare announced on Thursday that the Australian Therapeutic Goods Administration or the TGA has granted approval to Bayer Healthcare for EYLEA injection.

The EYLEA injection is for the treatment of patients with neovascular age-related macular degeneration at a recommended dose of 2 milligrams via intravitreal injection per month for three consecutive months, followed by 2 milligrams via intravitreal injection every two months.

EYLEA Injection, known in the scientific literature as VEGF Trap-Eye, is a recombinant fusion protein, consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. EYLEA acts as a soluble decoy receptor that binds VEGF-A and placental growth factor (PlGF) and thereby can inhibit the binding and activation of these cognate VEGF receptors.

"The approval of EYLEA represents an important new option for wet AMD patients in Australia," said George D Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories. "EYLEA allows for clinical efficacy that is non-inferior to monthly ranibizumab, but with fewer injections and less frequent office visits. We believe that this may help reduce treatment challenges for wet AMD patients and their physicians in Australia."

Bayer Healthcare plans to launch EYLEA in Australia in the second half 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Sarah Palin, former Alaska governor and vice-presidential candidate, filed a defamation lawsuit against The New York Times Co. on Tuesday for the alleged defamation in a recent editorial. In the lawsuit, which was filed in the United States District Court for the Southern District of New York, Palin stated that the editorial falsely portrayed her as responsible for inciting the 2011 shooting of D Dutch consumer electronics giant Philips Electronics NV Wednesday announced a definitive merger agreement to buy Spectranetics Corp., a vascular intervention and lead management solutions provider. Under the deal, Philips will commence a tender offer to buy Spectranetics for $38.50 per share, to be paid in cash upon completion. The implied enterprise value is approximately 1.9 billion euros. Samsung Electronics Co. is reviving its Galaxy Note 7 premium smartphone, which was recalled last year over faulty battery issues. A refurbished version of the smartphone with different components under the name Galaxy Note 7 Fandom Edition or FE will be coming to retailers' shelves on July 7, reports said.
comments powered by Disqus
Follow RTT